San Antonio Breast Cancer Symposium | Conference

Dr. Hurvitz on the Results of Subgroup Analyses From DESTINY-Breast03 in HER2+ Breast Cancer

December 9th 2021

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Pyrotinib Plus Capecitabine Shows Improved OS Over Lapatinib in HER2+ Breast Cancer

December 9th 2021

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer

Efficacy of Pertuzumab/Trastuzumab Deruxtecan Combo Under Investigation in DESTINY-Breast09 for HER2+ Breast Cancer

December 9th 2021

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

Adjuvant Approaches Reduce Risk of Distant Recurrence in HER2+ Early Stage Breast Cancer

December 9th 2021

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

Zanidatamab/Chemo Showcases Early Safety, Antitumor Activity in HER2+ Breast Cancer

December 9th 2021

The addition of the bispecific antibody zanidatamab to single-agent chemotherapy was found to produce promising antitumor activity with acceptable tolerability in heavily pretreated patients with HER2-positive breast cancer.

Addition of Chemo to Endocrine Therapy Yields Survival Benefit in Premenopausal HR+/HER2- Breast Cancer

December 8th 2021

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.

Tucatinib Plus Palbociclib/Letrozole Prolongs CNS-PFS in HR+/HER2+ Breast Cancer

December 8th 2021

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

Aromatase Inhibitors Significantly Reduce Recurrence in Premenopausal ER+ Breast Cancer

December 8th 2021

Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.

New Data Support Use of Palbociclib in Black and Hispanic Patients With HR+, HER2– Breast Cancer

December 8th 2021

Safety and efficacy data from a pooled pooled analysis confirm that patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer can be treated with palbociclib plus endocrine therapy.

Higher Incidence of Treatment Modifications Confers Worse Outcomes for Black Patients With Breast Cancer

December 8th 2021

Black patients with breast cancer were more likely to experience treatment modifications or discontinuations in the neoadjuvant setting compared with White patients.

Dr. Kalinsky on Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

December 8th 2021

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Frontline Ribociclib/Letrozole Improves OS in Postmenopausal HR+ Breast Cancer, Irrespective of Metastatic Site

December 8th 2021

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer

December 8th 2021

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.

Higher Oncotype DX Scores Predict for Improved Endocrine Therapy Compliance in ER+ Breast Cancer

December 8th 2021

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

December 8th 2021

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Datopotamab Deruxtecan Produces Encouraging Clinical Activity in Advanced TNBC

December 8th 2021

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

Entinostat/Exemestane Improves PFS in Chinese Patients With Advanced HR+ Breast Cancer

December 7th 2021

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

Adjuvant Pembrolizumab Sustains Benefit Across TNBC Subgroups

December 7th 2021

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.

Final Results from PALLAS Study Confirm Lack of Benefit in Adding Palbociclib to ET in Early HR+, HER2- Breast Cancer

December 7th 2021

Adding adjuvant palbociclib to standard endocrine therapy did not improve outcomes in patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer.

Pembrolizumab Plus Chemotherapy Represents New Standard of Care for Metastatic TNBC With PD-L1 CPS ≥10

December 7th 2021

Pembrolizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival vs chemotherapy alone in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer who have a PD-L1 combined positive score of 10 or higher.